INTRODUCTION The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.… (More)
+ 800 mg of ribavirin daily + telaprevir (750 mg/ 8 h) she achieved undetectable HCV-RNA at weeks 4 and 12. Treatment was complicated by severe anaemia, requiring pegy-lated interferon and ribavirin dose reduction and blood transfusion. HCV-RNA remained ,15 IU/L, and she continued on pegylated interferon + ribavirin treatment. HIV-RNA remained undetectable… (More)
BACKGROUND Cerebrospinal fluid (CSF) viral escape is a concern in ritonavir-boosted protease inhibitors monotherapy. The aim was to assess HIV-RNA, biomarkers of immune activation and neurodegeneration, and atazanavir concentrations in CSF of patients on successful long-term atazanavir/ritonavir (ATV/r) monotherapy. METHODS This is a substudy of the… (More)
INTRODUCTION Unboosted atazanavir (ATV) including regimens have been investigated as a ritonavir-sparing simplification strategy. No data are available on removal of one NRTI in subjects effectively treated with unboosted atazanavir+2NRTIs. We present the 48-week virological efficacy and safety of unboosted atazanavir plus lamivudine (3TC) or emtricitabine… (More)
Purpose of the study We determined the prevalence of type-2 diabetes melli-tus (DM) in HIV infected (HIV+) and uninfected (HIV-) subjects.